Heart failure with preserved ejection fraction


Authors: Jindřich Špinar 1;  Jiří Vítovec 2;  Lenka Špinarová 2
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice 1;  I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně 2
Published in: Vnitř Lék 2016; 62(7-8): 646-651
Category: Reviews

Tento článek věnujeme našemu příteli prof. MUDr. Milanovi Kvapilovi, CSc., k jeho významnému jubileu a přejeme mu hodně zdraví do dalších let, a aby nás ještě dlouho učil, jak správně léčit diabetes mellitus, třeba u nemocných se srdečním selháním.

Overview

Heart failure with preserved ejection fraction occurs almost with the same frequency as heart failure with reduced ejection fraction. The diagnosis is based on echocardiography with evidence-based ejection fraction over 50 %, or with left atrial enlargement and left ventricular hypertrophy, and specification of natriuretic peptides. BNP 35 pg/ml and NT-proBNP 125 pg/ml are considered the limits of the norm for chronic heart failure. The treatment of heart failure with preserved ejection fraction lacks clear evidence of mortality reduction, diuretics are recommended to remove symptoms, ACE inhibitors or sartans and beta-blockers to improve the prognosis. Anticoagulation treatment is recommended for atrial fibrillation and possibly digoxin, hypolipidemics for patients in secondary prevention. An important goal of the treatment is the control of accompanying diseases such as hypertension, diabetes mellitus and ischemic heart disease.

Key words:
accompanying diseases – treatment – heart failure – heart failure with preserved ejection fraction


Sources

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.

2. Špinar J, Vítovec J, Hradec J et al. Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure. Cor et Vasa 2012; 54(2): e113-e134. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2012.03.002>.

3. Špinar J, Vítovec J, Hradec J et al. Doporučený postup České kardiologické společnosti pro diagnostiku a léčbu chronického srdečního selhání 2011. Cor et Vasa 2012; 54(3–4): 161–182.

4. Hradec J. Diastolické srdeční selhání. In: Habilitační a inaugurační přednášky na 1. lékařské fakultě UK v Praze 2004. Galén: Praha 2005: 148–154. ISBN 80–7262–338–9.

5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93(9): 1137–1146.

6. Stewart S, MacIntyre K, Hole DJ et al. More “malignant” than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3): 315–322.

7. Rosolová H, Čech J, Simon J et al. Short to long term mortality of patients hospitalized in the Czech Republic – report from the EuroHeart Failure Survey. Eur J Heart Fail 2005; 7(5): 780–783.

8. Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83(5): 505–510.

9. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355(3): 260–269.

10. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347(3): 161–167.

11. Garcia MJ, Thomas JD, Klein AL. New doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32(4): 865–875.

12. Ommen SR, Nishimura RA, Appleton CP et al. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures. Circulation 2000; 102(15): 1788–1794.

13. Nagueh SF, Appleton ChP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10(2): 165–193.

14. Cleland J, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338–2345.

15. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456–2467.

16. Bangalore S, Messerli FH, Kostis JB et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50(7): 563–572.

17. Bangalore S, Bhatt DL, Steg PG et al. β-blockers and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014; 7(6): 872–881.

18. Bangalore S, Makani H, Radford M et al. Clinical outcomes with β-blockers for myocardial infarction: a metaanalysis od randomized trials. Am J Med 2014; 127(10): 939–953.

19. Špác J. Jsou betablokátory stále moderní léky? Acta medicinae 2016; 5(2): 50–55.

20. Misumida N, Harjai K, Kernis S et al. Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A meta-analysis. J Cardiovasc Pharmacol Ther; 21(3): 280–285. Dostupné z DOI: <http://dx.doi.org/10.1177/1074248415608011>.

21. Faris RF, Flather M, Purcell H et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012; (2): CD003838.

22. Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a metaanalysis of randomized controlled trials. Int J Cardiol 2002; 82(2): 149–158.

23. [The Digitalis Investigation Group]. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336(8): 525–533.

24. Beemath A, Stein PD, Skaf E et al. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006; 98(6): 793–795.

25. Witt BJ, Gami AS, Ballman KV et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007; 13(6): 489–496.

26. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29):2315–2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>.

27. Zinman B, Wanner CH, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 7-8

2016 Issue 7-8

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account